Akela Pharma Inc. AKLPF

[e-mail]

[modulex]

December 1, 2012

Registered Office and Head Office of TMX Group
The Exchange Tower
130 King Street West
Toronto, ON
M5X 1J2


RE: AKELA PHARMA INC. (AKL-Toronto Stock Exchange)
___________________________________________________________

To Whom it may Concern:

I am noticing that the above-noted company has been halted from trading as of November 23, 2012, without notification to its shareholders.

I have attempted on November 30, 2012 to contact management for a follow-up on this matter, having yet received no reply.

The company is also reported having moved its headquarters from the State of Texas to the State of California, again without updating its shareholders.

The company's stock has traded on relatively high volumes in the past three months, in a downward trend, to close at $0.01 on the day prior to its halting.

It is obviously clear that the company is neglectful to its shareholders by "running away and hiding".

I would therefore like to know from the TMX Group the reason(s) that prompted the stock to be halted on November 23, 2012 and what recourse(s) is/are available to shareholders.

Does the TMX Group or perhaps the Ontario Securities Commission or IIROC (Investment Industry Regulatory Organization of Canada) have any input/scope of intervention to bring the company to explain itself as to why it behaved inappropriately and take punitive actions against the company?

I am forwarding herebelow my e-mail sent to Akela Pharma Inc. President and CEO on November 30, 2012.
_______________________________________________________________________________________

[e-mail]

November 30, 2012

Mr. Rudy J. Emmelot
President and Chief Executive Officer
Akela Pharma Inc.

Mr. Emmelot:

While doing my year-end 2012 financial review this morning, I am noticing that the stock (AKL-Toronto) has been halted from trading as of November 23, 2012, without notice to shareholders.

The company's website WWW.AKELAPHARMA.COM does not display any business address and only refers to the following contact information:

For Formulation Development, Manufacturing & Analytical solutions:
Toll Free 866-977-7771

For General Inquiries:

Main 512-834-0449
Fax [phone]

A separate verification brought me to find out that Corporate Headquarters have moved from 11501 Domain Drive, Austin, Texas - 78758, United States, Phone: [phone] - Fax: [phone] to the State of California, at no specified address.

PharmaForm moving to San Diego

Oct16-2012

Contract manufacturer PharmaForm, a subsidiary of Akela Pharma, has announced plans to move from Austin, TX to the San Diego, CA area. The company offers formulation and manufacturing services for numerous dosage forms, including nasal sprays and inhalation powders.

PharmaForm President and CEO Rudy J. Emmelot commented, “We are excited about our move to San Diego and becoming part of the San Diego and California pharmaceutical and biotechnology centers. The Torreyana facility allows PharmaForm to expand beyond its current expertise of formulation development and solubility solutions for the pharmaceutical and biotechnology industries.”
The company’s corporate headquarters will be located at the new site in Torrey Pines, along with R&D, formulation, and manufacturing units.

I am questioning WHY:

The company's stock was halted on November 23, 2012?

The company did not issued a News Release about the stock halted on November 23, 2012?

The company has relocated without updating its website accordingly?

The company's telephone number indicated above (512-834-0449) refers to a telephone number in the State of Texas and the company is now in the State of California, which area code is 619?

Awaiting your reply.

Luc Proulx

[e-mail]

Akela Pharma Inc. shareholder